Silence Therapeutics (XRP2) Stock Forecast & Price Target

37 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

XRP2 Analyst Ratings

Moderate Buy

5 Buy

0 Hold

1 Sell

Based on 6 analysts giving stock ratings to

Silence

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

XRP2 Stock 12 Month Forecast

Average Price Target

€31.67

▲(233.41% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Silence Therapeutics in the last 3 months. The average price target is €31.67 with a high forecast of €64.20 and a low forecast of €3.42. The average price target represents a 233.41% change from the last price of €9.50.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","65":"€65","17.75":"€17.75","33.5":"€33.5","49.25":"€49.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":64.20446775,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€64.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31.67420409,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€31.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.42423828,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€3.42</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,17.75,33.5,49.25,65],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.4,14.538805211538463,18.677610423076924,22.81641563461539,26.95522084615385,31.09402605769231,35.23283126923077,39.37163648076923,43.510441692307694,47.649246903846155,51.788052115384616,55.92685732692308,60.065662538461545,{"y":64.20446775,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.4,12.036477237692308,13.672954475384616,15.309431713076922,16.94590895076923,18.582386188461538,20.218863426153845,21.855340663846153,23.49181790153846,25.12829513923077,26.764772376923077,28.40124961461538,30.037726852307692,{"y":31.67420409,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.4,9.863402944615386,9.32680588923077,8.790208833846155,8.253611778461538,7.7170147230769235,7.180417667692308,6.643820612307692,6.107223556923077,5.570626501538461,5.034029446153846,4.49743239076923,3.9608353353846155,{"y":3.42423828,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.84,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.14,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.55,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.1,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.78,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.32,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.32,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.15,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.65,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.35,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.4,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€64.20

Average Price Target€31.67

Lowest Price Target€3.42

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Keay Nakae

Chardan Capital

―

Buy

―

Reiterated

08/16/26

Analysts Offer Insights on Healthcare Companies: Silence Therapeutics (NASDAQ: SLN), Cardinal Health (NYSE: CAH) and Allogene Therapeutics (NASDAQ: ALLO)

Patrick Trucchio

H.C. Wainwright

€64.2

Buy

575.84%

Upside

Reiterated

08/14/26

Analysts Offer Insights on Healthcare Companies: Jade Biosciences (NASDAQ: JBIO), Silence Therapeutics (NASDAQ: SLN) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Michael Ulz

Morgan Stanley

€21.4→€27.39

Buy

188.36%

Upside

Assigned

08/11/26

Silence Therapeutics (SLN) Receives a Buy from Morgan Stanley

Myles Minter

William Blair

―

Buy

―

Reiterated

08/10/26

Analysts Are Bullish on Top Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Silence Therapeutics (SLN)

Richard Law CFA

Goldman Sachs

€3.42

Sell

-63.96%

Downside

Reiterated

07/27/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Vericel (NASDAQ: VCEL) and Silence Therapeutics (NASDAQ: SLN)

Prakhar Agrawal

Cantor Fitzgerald

―

Buy

―

Initiated

06/24/26

Silence Therapeutics initiated with an Overweight at Cantor FitzgeraldSilence Therapeutics initiated with an Overweight at Cantor Fitzgerald

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Keay Nakae

Chardan Capital

―

Buy

―

Reiterated

08/16/26

Analysts Offer Insights on Healthcare Companies: Silence Therapeutics (NASDAQ: SLN), Cardinal Health (NYSE: CAH) and Allogene Therapeutics (NASDAQ: ALLO)

Patrick Trucchio

H.C. Wainwright

€64.2

Buy

575.84%

Upside

Reiterated

08/14/26

Analysts Offer Insights on Healthcare Companies: Jade Biosciences (NASDAQ: JBIO), Silence Therapeutics (NASDAQ: SLN) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Michael Ulz

Morgan Stanley

€21.4→€27.39

Buy

188.36%

Upside

Assigned

08/11/26

Silence Therapeutics (SLN) Receives a Buy from Morgan Stanley

Myles Minter

William Blair

―

Buy

―

Reiterated

08/10/26

Analysts Are Bullish on Top Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Silence Therapeutics (SLN)

Richard Law CFA

Goldman Sachs

€3.42

Sell

-63.96%

Downside

Reiterated

07/27/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Vericel (NASDAQ: VCEL) and Silence Therapeutics (NASDAQ: SLN)

Prakhar Agrawal

Cantor Fitzgerald

―

Buy

―

Initiated

06/24/26

Silence Therapeutics initiated with an Overweight at Cantor FitzgeraldSilence Therapeutics initiated with an Overweight at Cantor Fitzgerald

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ODTXOdyssey Therapeutics, Inc.

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Silence Therapeutics

3 Months

Myles MinterWilliam Blair

Success Rate

13/20 ratings generated profit

Average Return

+15.77%

Copying Myles Minter's trades and holding each position for 3 Months would result in 65.00% of your transactions generating a profit, with an average return of +15.77% per trade.

1 Year

Myles MinterWilliam Blair

Success Rate

13/20 ratings generated profit

Average Return

+30.69%

Copying Myles Minter's trades and holding each position for 1 Year would result in 65.00% of your transactions generating a profit, with an average return of +30.69% per trade.

2 Years

Patrick TrucchioH.C. Wainwright

Success Rate

17/21 ratings generated profit

Average Return

+99.78%

Copying Patrick Trucchio's trades and holding each position for 2 Years would result in 80.95% of your transactions generating a profit, with an average return of +99.78% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

XRP2 Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, XRP2 has received 10 Buy Ratings, 0 Hold Ratings, and 1 Sell Ratings. XRP2 average Analyst price target in the past 3 months is 31.67.

Each month's total comprises the sum of three months' worth of ratings.

XRP2 Financial Forecast

XRP2 Earnings Forecast

Next quarter’s earnings estimate for XRP2 is -€0.10 with a range of -€0.24 to -€0.06. The previous quarter’s EPS was -€0.08. XRP2 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year XRP2 has Performed in-line its overall industry.

XRP2 Sales Forecast

Next quarter’s sales forecast for XRP2 is €106.37K with a range of €0.00 to €343.12K. The previous quarter’s sales results were €0.00. XRP2 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year XRP2 has Performed in-line its overall industry.

XRP2 Stock Forecast FAQ

What is DE:XRP2’s average 12-month price target, according to analysts?

Based on analyst ratings, Silence Therapeutics Plc’s 12-month average price target is 31.67.

What is DE:XRP2’s upside potential, based on the analysts’ average price target?

Silence Therapeutics Plc has 233.41% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Silence Therapeutics Plc a Buy, Sell or Hold?

Silence Therapeutics Plc has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 0 hold ratings and 1 sell ratings.

What is Silence Therapeutics Plc’s share price target?

The average share price target for Silence Therapeutics Plc is 31.67. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €64.20 ,and the lowest forecast is €3.42. The average share price target represents 233.41% Increase from the current price of €9.5.

What do analysts say about Silence Therapeutics Plc?

Silence Therapeutics Plc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of Silence Therapeutics Plc?

To buy shares of DE:XRP2, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Silence Therapeutics (XRP2) Stock Forecast & Price Target

XRP2 Analyst Ratings

XRP2 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Silence Therapeutics

XRP2 Analyst Recommendation Trends

XRP2 Financial Forecast

XRP2 Earnings Forecast

XRP2 Sales Forecast

XRP2 Stock Forecast FAQ

Detailed List of Analyst Forecasts